Carl L. G. Hansen
Known title: Chief Executive OfficerCIK: 0001834412
Associated companies
Transaction History
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 11/25/2024 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 9/20/2024 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 5/31/2024 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 2/26/2024 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 11/23/2023 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 8/24/2023 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 5/26/2023 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 2/22/2023 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 11/18/2022 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 8/18/2022 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 5/18/2022 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 56,125 | $152K | 2/22/2022 | View on chart |
| ABCL | ▲ Buy | Option Exercise | 224,500 | $3.4M | 11/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results
UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results. UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.